123 results on '"Prica, Anca"'
Search Results
2. Health care utilization and costs for frail vs nonfrail patients with diffuse large B-cell lymphoma
3. The association between nutritional risk index and ICU outcomes across hematologic malignancy patients with acute respiratory failure
4. The Impact of CD34+ Cell Collection Yields for Autologous Transplant on Survival Outcomes in Multiple Myeloma
5. Very late relapse in Hodgkin lymphoma: Characterizing an understudied population
6. Health-related quality of life in early-stage Hodgkin lymphoma: a longitudinal analysis of the ABVD arm in the randomized controlled trial HD.6
7. Post Salvage Therapy Autologous Transplant for Relapsed Myeloma, Ongoing Relevance within Modern Treatment Paradigms?
8. Predicting the Risks of Aggressive-Intent Chemotherapy Toxicity in Older Patients With Lymphoma: A Prospective Observational Pilot Study
9. International Prognostic Score for Nodular Lymphocyte–Predominant Hodgkin Lymphoma.
10. Cost-effectiveness analysis of allogeneic versus autologous stem cell transplant versus chemo-immunotherapy for early relapse of follicular lymphoma within 2 years of initial therapy
11. Light Chain Amyloidosis (AL) Associated With B Cell Lymphoma a Single Center Experience
12. A Prospective Economic Analysis of Early Outcome Data From the Alliance A041202/ CCTG CLC.2 Randomized Phase III Trial Of Bendamustine-Rituximab Compared With Ibrutinib-Based Regimens in Untreated Older Patients With Chronic Lymphocytic Leukemia
13. A risk model for relapsed/refractory aggressive NHL integrating clinical risk factors and pretransplant Deauville score
14. Cost-effectiveness of first-line treatment options for patients with advanced-stage Hodgkin lymphoma: a modelling study
15. Toxicity and survival outcomes of autologous stem cell transplant in multiple myeloma patients with renal insufficiency: an institutional comparison between two eras
16. Indolent lymphoma care delivery and outcomes during the COVID‐19 pandemic in Ontario, Canada.
17. Red cell transfusion thresholds in outpatients with myelodysplastic syndromes: Combined results from two randomized controlled feasibility studies.
18. Red cell transfusion thresholds in outpatients with myelodysplastic syndromes: Results of a pilot randomized trial RBC‐ENHANCE.
19. Single-center Experience in Treating Patients With t(4;14) Multiple Myeloma With and Without Planned Frontline Autologous Stem Cell Transplantation
20. Ibrutinib Plus RCHOP versus RCHOP Only in Young Patients with Activated B-Cell-like Diffuse Large B-Cell Lymphoma (ABC-DLBCL): A Cost-Effectiveness Analysis.
21. Hematopoietic Cell Transplantation Trends and Outcomes in Canada: A Registry-Based Cohort Study.
22. The Impact of CD34+ Cell Collection Yields for Autologous Transplant on Survival Outcomes in Multiple Myeloma.
23. Mortality among patients with diffuse large B-cell lymphoma and mental disorders: a population-based study.
24. Impact of 18F-fluorodeoxyglucose PET/CT in the management of patients with plasma cell disorders
25. Cyclophosphamide and Bortezomib With Prednisone or Dexamethasone for the Treatment of Relapsed and Refractory Multiple Myeloma
26. Outcomes of patients with indolent lymphoma treated with bendamustine plus rituximab compared to rituximab plus CVP or CHOP chemoimmunotherapy in Ontario.
27. Virtual Care During the COVID-19 Pandemic for Patients With Hematologic Malignancies: A Single-Institution Experience.
28. Bendamustine and rituximab is well‐tolerated and efficient in the treatment of indolent non‐Hodgkin's lymphoma and mantle cell lymphoma in elderly: A single center observational study.
29. Combination of FDG PET/CT Radiomics and Clinical Parameters for Outcome Prediction in Patients with Hodgkin's Lymphoma.
30. Rapidity and Quality of Response to Steroid-Based Induction Therapy, Without the Addition of Novel Agents, Does Not Affect Post Transplant Outcomes in Multiple Myeloma
31. Cost-Effectiveness Analysis of Frontline Polatuzumab-Rituximab, Cyclophosphamide, Doxorubicin, and Prednisone and/or Second-Line Chimeric Antigen Receptor T-Cell Therapy Versus Standard of Care for Treatment of Patients With Intermediate- to High-Risk...
32. Impact of Geriatric Assessment and Management on Quality of Life, Unplanned Hospitalizations, Toxicity, and Survival for Older Adults With Cancer: The Randomized 5C Trial.
33. Management of Marginal Zone Lymphoma: A Canadian Perspective.
34. Clinical utility of interim CT scans in patients receiving chemoimmuntherapy for first line treatment of follicular lymphoma.
35. Clinical significance of clonal hematopoiesis in the setting of autologous stem cell transplantation for lymphoma.
36. Frontline Rituximab Monotherapy Induction Versus a Watch and Wait Approach for Asymptomatic Advanced-Stage Follicular Lymphoma: A Cost-Effectiveness Analysis
37. Pyoderma gangrenosum secondary to azacitidine in myelodysplastic syndrome
38. Long-term follow up of relapsed/refractory non-Hodgkin lymphoma patients treated with single-agent selinexor – a retrospective, single center study.
39. Safety and efficacy of thrombopoietin-receptor agonists in myelodysplastic syndromes: a systematic review and meta-analysis of randomized controlled trials
40. Guillain-Barré syndrome as an early manifestation of angioimmunoblastic T-cell lymphoma.
41. Risk stratification for relapsed/refractory classical Hodgkin lymphoma integrating pretransplant Deauville score and residual metabolic tumor volume.
42. Fixed duration vs. prolonged duration treatment after first line therapy in patients with systemic light chain amyloidosis.
43. Kinetics of response to first‐ and second‐line therapies in multiple myeloma: Assessment by both M‐spikes and light chains.
44. The Use of Virtual Care in Patients with Hematologic Malignancies: A Scoping Review.
45. Combined modality therapy versus chemotherapy alone as an induction regimen for primary central nervous system lymphoma: a decision analysis
46. Positron-emission tomography-based staging is cost-effective in early-stage follicular lymphoma.
47. Light Chain Amyloidosis (AL) Associated With B Cell Lymphoma a Single Center Experience.
48. Cardiovascular Risk Associated With Ibrutinib Use in Chronic Lymphocytic Leukemia: A Population-Based Cohort Study.
49. Minimization of resource utilization data collected within cost-effectiveness analyses conducted alongside Canadian Cancer Trials Group phase III trials.
50. Association of Thoracic Computed Tomographic Measurements and Outcomes in Patients with Hematologic Malignancies Requiring Mechanical Ventilation.
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.